{"filings":[{"id":442643,"accession_number":"0001378325-26-000019","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2026-05-14T20:08:08+00:00","items":["2.02","9.01"],"status":"ready","headline":"CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.","Gross margin 48% vs 54% YoY due to impact of U.S. trade policies and tariffs.","Operating expenses $8.4M, up $1.5M from CMOS sensor development with Canon and Colon clinical trials.","Cash $17.9M; completed $14M PIPE financing on March 16, 2026.","Pipeline: AI-assisted reading feature on track for mid-2026 FDA clearance; CapsoCam Colon 510(k) submission Q3 2026; pancreatic cancer study enrolled first patient May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":2792000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103413,"accession_number":"0001378325-26-000008","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CapsoVision reports 15% revenue growth in FY2025; completes $14M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $3.9M (+13% YoY); full year $13.6M (+15% YoY) driven by higher capsule sales.","Gross margin stable at 50% Q4 and 53% full year (vs 54% prior year).","Operating expenses $9.4M Q4 (+$3.0M YoY); full year $32.7M (+$6.4M) on CMOS sensor development and public company costs.","Cash $10.1M at Dec 31, 2025; completed $14M private placement in March 2026.","Submitted FDA 510(k) for AI-assisted module; 161,000+ patients used CapsoCam Plus as of Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103412,"accession_number":"0001378325-26-000004","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"CapsoVision closes $14M private placement; reports preliminary FY2025 revenue of $13.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $14M gross via 2.87M shares at $4.883 (5% discount to March 16 close); closed March 16, 2026.","Preliminary Q4 2025 revenue $3.9M; full-year 2025 revenue $13.6M; cash & equivalents ~$10.1M as of Dec. 31, 2025.","Abandoned first-gen CapsoCam Colon 510(k); prioritizing second-gen with improved imaging; pivotal study enrolling ~800 patients; over 500 enrolled; expects 510(k) submission in Q3 2026.","Breakthrough Device Designation for CapsoCam UGI denied in Jan 2026; plans to resubmit after ~90-patient study starting Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103411,"accession_number":"0001378325-26-000002","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CapsoVision amends Canon development deal; total fee increased by $1.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total fee under CMOS image sensor development agreement with Canon raised by $1.0M due to increased features.","Remaining development fee of ~$3.1M (original) adjusted upward; additional unit price amount unchanged.","Amendment effective March 9, 2026; original agreement dated July 15, 2025.","CapsoVision will continue to pay remaining balance per original Articles 12.4-12.6."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119648,"accession_number":"0001378325-25-000043","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CapsoVision submits 510(k) to FDA for AI-assisted reading module for CapsoCam Plus","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted 510(k) to FDA for proprietary AI-assisted module for CapsoCam Plus capsule endoscopy system.","AI module designed to improve detection of clinically significant pathology and reduce clinician review time.","Company plans to commence U.S. commercialization following FDA clearance.","CapsoVision claims it is the only capsule endoscopy company with in-house AI core competency.","Cloud-based architecture eliminates need for on-site servers, reducing cost and IT maintenance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119647,"accession_number":"0001378325-25-000039","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CapsoVision Q3 revenue $3.5M (+19% YoY); FDA submission for pancreatic cancer capsule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.5M (+19% YoY); new accounts up 31%; CapsoCam Plus used by 151k patients.","Gross profit $1.9M (+16%); gross margin 54% vs 56% in Q3 2024.","Operating expenses $9.9M (+$2.5M) driven by Canon CMOS development and public company costs.","Cash $17.8M; July 2025 IPO net proceeds $23.4M.","Submitted FDA Breakthrough Device Designation for early-stage pancreatic cancer detection; David Garcia appointed SVP Finance."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":9636000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119646,"accession_number":"0001378325-25-000031","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CapsoVision files FDA Breakthrough Device application for pancreatic cancer screening capsule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted BDD application to FDA on Nov 6, 2025 for CapsoCam UGI capsule to detect early-stage pancreatic ductal adenocarcinoma.","If granted, the designation would enable accelerated development and closer FDA collaboration on clinical studies.","CapsoCam UGI is a non-invasive, pill-shaped camera with panoramic imaging to visualize duodenal papilla changes.","Pancreatic cancer has 8-10% five-year survival rate; no non-invasive screening exists for the general population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119645,"accession_number":"0001378325-25-000027","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CapsoVision appoints David Garcia as SVP of Finance and principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Nov 3, 2025; Garcia previously VP of FP&A at Matterport, led IPO and M&A.","Annual base salary $300,000; granted option to purchase 165,000 shares under 2025 Equity Plan.","Option vests 25% on Nov 3, 2026, then 36 monthly installments; exercise price = Nov 3 closing price.","Eligible for quarterly bonus of $12,500; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136226,"accession_number":"0001378325-25-000022","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CapsoVision Senior Director of Clinical Affairs to retire; Keri Jorgenson promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rebecca Petersen to retire as Senior Director of Clinical Affairs effective Oct 15, 2025.","Keri Jorgenson promoted to Director of Clinical Operations, assuming clinical development responsibilities.","Petersen to provide consulting at $150/hour starting Oct 16; unvested stock options continue vesting.","Company expects no disruption to clinical development operations during transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136225,"accession_number":"0001378325-25-000018","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Kevin Lundquist steps down; CapsoVision begins successor search","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Lundquist resigned as CFO effective Aug 27, 2025; company started search for replacement.","Severance includes 6 months base salary, prorated bonus of $33,333, and COBRA coverage.","Unvested options for 86,806 shares will accelerate vesting; exercisable until Sep 1, 2028.","Lundquist will provide consulting for up to 6 months through Feb 28, 2026 under Consulting Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136224,"accession_number":"0001378325-25-000008","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CapsoVision Q2 revenue $3.3M (+17% YoY); IPO closes raising $23.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.3M, up 17% YoY, driven by higher CapsoCam Plus capsule sales.","Gross profit $1.8M (55% margin) vs. $1.6M (56%) in Q2 2024.","Operating expenses $6.5M, down $0.4M from prior year due to reduced clinical trial costs.","Closed IPO on July 3, 2025, net proceeds of $23.4M; cash was $1.1M at June 30.","Filed 510(k) for CapsoCam Colon in June 2025; AI module addition targeted for FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":6098000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136223,"accession_number":"0001378325-25-000002","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CapsoVision signs $4.1M CMOS sensor development agreement with Canon; overallotment yields $0.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Development agreement with Canon for CMOS image sensor samples; total fee ~$4.1M, $1M cash upfront, remainder via unit price add-on in future purchase agreement.","Samples to be used for evaluation, clinical evaluation, and FDA 510(k) clearance for future capsule endoscopy products.","Capso submitted FDA 510(k) for first-generation CapsoCam Colon on June 10, 2025; second generation planned before commercialization.","Underwriters exercised partial overallotment: 129,978 shares issued for net proceeds ~$600,000; additional warrants for 3,898 shares at $6.25 exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136222,"accession_number":"0001193125-25-155527","cik":1378325,"company_name":"CapsoVision, Inc","ticker":"CV","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"CapsoVision closes IPO of 5.5M shares at $5.00; gross proceeds $27.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed IPO of 5,500,000 shares at $5.00/share, raising $27.5M in gross proceeds.","Shares began trading on Nasdaq Capital Market on July 2, 2025 under ticker CV.","Underwriters granted 30-day overallotment option for up to an additional 825,000 shares.","Company issued Representatives' Warrants for 165,000 shares at $6.25, exercisable from February 2026.","Officers, directors, and certain stockholders entered 6-month lock-up agreements restricting share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340252001.82640946,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}